Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
159M
-
Number of holders
-
250
-
Total 13F shares, excl. options
-
93.1M
-
Shares change
-
+3.71M
-
Total reported value, excl. options
-
$1.66B
-
Value change
-
+$72.1M
-
Put/Call ratio
-
0.79
-
Number of buys
-
136
-
Number of sells
-
-96
-
Price
-
$17.79
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q2 2024
307 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q2 2024.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 250 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 93.1M shares
of 159M outstanding shares and own 58.62% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.7M shares), BlackRock Inc. (11.4M shares), STATE STREET CORP (6.7M shares), Soleus Capital Management, L.P. (3.65M shares), Pictet Asset Management Holding SA (3.24M shares), GEODE CAPITAL MANAGEMENT, LLC (3.21M shares), Deep Track Capital, LP (2.87M shares), Opaleye Management Inc. (2.28M shares), GOLDMAN SACHS GROUP INC (2.08M shares), and BANK OF AMERICA CORP /DE/ (2.08M shares).
This table shows the top 250 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.